Day 2 - UTC+08:00
Delving into the transformative potential of nucleic acid-based therapies and enabling technologies, with insights into APAC’s unique investment opportunities, including emerging biotech hubs, innovative startups, and regional strengths in clinical trials and manufacturing
Exploring collaborative investment strategies to accelerate development pipelines and expand market access for nucleic acid technologies across APAC.
- Carl Firth - Partner, Panacea Capital
- Michelle Lynn Hall - General Partner, Entrée Bioventures
- Fong Ming Koh - Principle, LYFE Capital
- Yvonne Koh - Vice President, Therapeutics, ClavystBio
Examining the evolving regulatory frameworks for nucleic acid therapeutics across Asia-Pacific and Western regions, with a focus on harmonizing standards to support global innovation and accessibility.
Discussing challenges and opportunities in navigating diverse regulatory landscapes, including strategies for accelerating approvals and ensuring safety and efficacy in emerging RNA-based treatments.
- Jack Wong - CEO and Founder, Asia Regulatory Professionals Association (ARPA)
- Mimi Lee - Program Manager, Advanced Research Projects Agency for Health (ARPA-H)
Highlighting the future innovation potential of RNA therapeutics, focusing on next-generation approaches such as RNA editing, non-coding RNAs, and circular RNAs (circRNAs) to address complex diseases and advance precision medicine in Asia- Pacific
- Muthiah (Mano) Manoharan, PhD - Senior Vice President of Drug Innovation and Distinguished Research Scientist, Alnylam Pharmaceuticals
- Mohamed ElSayed - Executive Director, NATi